The overarching goal for my research is to develop new tools to address biological questions and new therapies to improve human health, taking advantage of my unique experience in organic and medicinal chemistry, drug delivery, material sciences, cell biology and preclinical studies. My laboratory has developed the first reversible reaction-based fluorescent probe to monitor glutathione (GSH) dynamics in living cells and the first potent and safe small molecule inhibitor (SMI) for steroid receptor coactivator-3 (SRC-3) as a novel targeted cancer therapy. Additionally, we develop novel antibody-drug conjugates to target P53 defective cancer.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Affiliations
Research Consortia
GCC Cluster for Cellular and Molecular Biophysics
Training Grants
The Cancer Therapeutics Training Program (CTTP)
Training Interdisciplinary Pharmacology Scientists
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.